Medical technology company Intelligent Bio Solutions (Nasdaq: INBS) demonstrated positive financial momentum in fiscal Q3 2025, with sequential revenue growth and improved operational efficiency. The company reported a 20% increase in revenue to $728,867, primarily attributed to strong cartridge sales that now represent 58% of total revenue.
Notably, the company experienced a substantial 91% year-over-year gross profit increase to $341,368. The net loss also significantly narrowed by $434,141, reducing to $2.54 million, indicating improved financial management and potential path toward profitability.
Strategic expansion remained a key focus for the company during the quarter. INBS added 35 new accounts, expanding its active customer base to over 450 organizations. The company's international growth strategy continues through strategic partnerships and system upgrades designed to support multilingual markets.
Technological innovation further supported the company's progress, with INBS securing its sixth U.S. patent and advancing regulatory efforts across key global markets. The company's Intelligent Fingerprinting Drug Screening System, which enables rapid drug testing through fingerprint sweat analysis, remains a core technological asset with potential applications across multiple industries.
The current customer segments for the company's technology include construction, manufacturing, engineering, transportation, logistics, drug treatment organizations, and coroner services. The system's ability to collect samples in seconds and deliver results within ten minutes presents a potentially transformative solution for workplace drug screening.
These developments suggest Intelligent Bio Solutions is making meaningful strides in establishing its non-invasive testing technology as a viable and efficient solution for rapid drug screening across diverse professional environments. The company's continued revenue growth, expanding customer base, and technological advancements indicate potential for future market penetration and technological innovation in the medical testing sector.
